RESEARCH

Thyroid cancer research is a critical piece of our mission.

OUR GRANT FUNDRAISING

Bite Me Cancer partners with The American Thyroid Association to directly fund thyroid cancer research grants. This program is geared toward budding researchers looking at new ways to approach thyroid cancer, and there is a rigorous review process for the research applicants.

In 2012, Bite Me Cancer set out with the goal to raise $57,500 to fund one of the grants. By the end of 2013, we did just that and became an official grant partner of ATA! Two years later in 2014, the final selection process was conducted by ATA’s review panel, and Bite Me Cancer chose a research grant.

Here's how it works:  Bite Me Cancer sends in a check to cover one-half of the funding for the first year of the research. Research progress is reviewed after year one by ATA to determine whether year two will be funded. If approved, Bite Me Cancer also pays for the second year of research. 

Since 2014, we have continued to raise funds each year for a research grant. As of 2019, ATA requires $50,000 for a 2-year grant instead of $57,500. You can see our researchers and their work below. We are very grateful for their efforts and that we can follow their progress directly.

ABOUT THE AMERICAN THYROID ASSOCIATION

Since 2012, Bite Me Cancer has been dedicated to trying to make a difference in Thyroid Cancer research with the hopes of being able to fund a 2-year grant in partnership with the American Thyroid Association (ATA).

The American Thyroid Association® (ATA) is dedicated to transforming thyroid care through clinical excellence, education, scientific discovery and advocacy in a collaborative community.

 
tc.research.dr.monteroconde.jpg

DR. CRISTINA MONTERO-CONDE - SEVENTH GRANT

Spanish National Cancer Research Center (CNIO), Madrid, Spain

tc.research.athanasios_bikas.jpg

DR. ANTHANASIOS BIKAS - SIXTH GRANT

Brigham & Women's Hospital

tc.research.dr.miles.jpg

DR. WAYNE MILES - FIFTH GRANT

Assistant Professor, Molecular Genetics, The Ohio State University Medical Center

tc.research.yu qin (judy).jpg

DR. YU QIN - FOURTH GRANT

Clinical Fellow, Endocrinology, MD Anderson Cancer Center

 
tc.research.dr.min.jpg

DR. IRENE MIN - THIRD GRANT

Weill Cornell Medicine in New York

Dr.-Boucai-photo-768x875.jpg

LAURA BOUCAI, MD - SECOND GRANT

Physician-Scientist, Memorial Sloan Kettering Cancer Center

tc.research.ramona dadu photo.jpg

RAMONA DADU, MD - FIRST GRANT

Assistant Professor, Department of Endocrine Neoplasia & Hormonal Disorders, M.D. Anderson Cancer Center

 
 

Spanish National Cancer Research Center (CNIO), Madrid, Spain

DR. CRISTINA MONTERO-CONDE, PHD - SEVENTH GRANT

“Discovering novel molecular nodes involved in MTC development and evolution.” This research project has the potential to identify molecular events that confer an outgrowth advantage to the tumor but at the same time a greater dependence on specific oncogenes or molecular networks. Therefore, such alterations could predict enhanced responses to selective molecules, such as the RET-targeted inhibitors Blu-667 (submitted for FDA approval) and LOXO-292 (recently FDA approved. In addition, the results of this proposal will generate the first map of allelic imbalance events in MTC.

In 2009, Cristina joined Dr. James Fagin´s laboratory at Memorial Sloan-Kettering Cancer Research Center (MSKCC) in New York. Her postdoctoral work focused on the characterization of resistance mechanisms to RAF and MEK kinase inhibitors. Dr. Montero-Conde discovered that resistance determinants vary among cancer types due to preferential self-regulation of specific RTKs, and critically on the autocrine expression or abundance of their respective ligands. The work was published in Cancer Discovery (2013) and prompted an editorial and extensive coverage in other journals. She also received the 2011 Endocrine Society Presidential Poster Award. Dr. Montero-Conde returned to the CNIO in 2014, and obtained a senior postdoctoral research grant from the Spanish Association for Cancer Research (AECC) in 2015. She has been steadily productive and her research currently focuses on the identification and characterization of the molecular hallmarks of medullary and follicular cell-origin thyroid cancer through genomic strategies, with special interest in those with a therapeutic application.

 s Blu-667 (submitted for FDA approval) and LOXO-292 (recently FDA approved. In addition, the results of this proposal will generate the first map of allelic imbalance events in MTC.